» Articles » PMID: 29120753

Mitochondrial OXPHOS Induced by RB1 Deficiency in Breast Cancer: Implications for Anabolic Metabolism, Stemness, and Metastasis

Overview
Journal Trends Cancer
Publisher Cell Press
Specialty Oncology
Date 2017 Nov 10
PMID 29120753
Citations 80
Authors
Affiliations
Soon will be listed here.
Abstract

A switch from catabolic to anabolic metabolism, a major hallmark of cancer, enables rapid cell duplication, and is driven by multiple oncogenic alterations, including PIK3CA mutation, MYC amplification, and TP53 loss. However, tumor growth requires active mitochondrial function and oxidative phosphorylation (OXPHOS). Recently, loss of the retinoblastoma (RB1) tumor suppressor in breast cancer was shown to induce mitochondrial protein translation (MPT) and OXPHOS. Here, we discuss how increased OXPHOS can enhance anabolic metabolism and cell proliferation, as well as cancer stemness and metastasis. Mitochondrial STAT3, FER/FER-T, and CHCHD2 are also implicated in OXPHOS. We propose that RB1 loss represents a prototypic oncogenic alteration that promotes OXPHOS, that aggressive tumors acquire lethal combinations of oncogenes and tumor suppressors that stimulate anabolism versus OXPHOS, and that targeting both metabolic pathways would be therapeutic.

Citing Articles

Recent Advances in Pineoblastoma Research: Molecular Classification, Modelling and Targetable Vulnerabilities.

Jiang Z, Allkanjari M, Chung P, Tran H, Ghanbari-Azarnier R, Wang D Cancers (Basel). 2025; 17(5).

PMID: 40075567 PMC: 11898778. DOI: 10.3390/cancers17050720.


Integrated multi-omics characterization of neuroblastoma with bone or bone marrow metastasis.

Huang K, Yang L, Ma Y, Cao L, Li S, Zhao Z Genes Dis. 2025; 12(3):101511.

PMID: 40070366 PMC: 11894310. DOI: 10.1016/j.gendis.2024.101511.


Steatotic liver disease in metastatic breast cancer treated with endocrine therapy and CDK4/6 inhibitor.

Malon D, Molto C, Prasla S, Cuthbert D, Pathak N, Berner-Wygoda Y Breast Cancer Res Treat. 2024; .

PMID: 39720971 DOI: 10.1007/s10549-024-07578-2.


Integrated analyses of multi-omic data derived from paired primary lung cancer and brain metastasis reveal the metabolic vulnerability as a novel therapeutic target.

Duan H, Ren J, Wei S, Yang Z, Li C, Wang Z Genome Med. 2024; 16(1):138.

PMID: 39593114 PMC: 11590298. DOI: 10.1186/s13073-024-01410-8.


The role of glycolysis in tumorigenesis: From biological aspects to therapeutic opportunities.

Cordani M, Michetti F, Zarrabi A, Zarepour A, Rumio C, Strippoli R Neoplasia. 2024; 58:101076.

PMID: 39476482 PMC: 11555605. DOI: 10.1016/j.neo.2024.101076.